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Are We Ready for Marginal Hepatitis B Core
Antibody–Positive Living Liver Donors?
Robert J. Fontana* and Robert M. Merion†
Adult-to-adult living donor liver transplantation(LDLT) is being performed in the United States
with increasing frequency because of the severe shortage
of cadaveric donor organs.1,2 For example, 42 of 89
Organ Procurement and Transplantation Network–
certified liver transplant programs (47%) reported hav-
ing performed at least one adult-to-adult LDLT in
2000, and 355 adult-to-adult LDLTs were performed
in the United States in 2002, with the latter accounting
for 6.6% of all liver transplantations.1,3 Patient and
graft survival rates in carefully selected adult living
donor liver transplant recipients have been similar to
those for cadaveric recipients; however the number of
patients and duration of follow-up are limited.4,5 In
addition, greater rates of biliary, infectious, and vascular
complications have been reported in adult living donor
liver transplant recipients compared with cadaveric
recipients.2-5
Information on outcomes of right-lobe liver donors
is limited because of the lack of a standardized fol-
low-up protocol and central registry. However, short-
term complications reported in adult living liver trans-
plant donors include blood transfusion (10% to 15%),
biliary complications (15% to 30%), and reoperation
(5%), among others.1-7 Although most healthy adult
living liver transplant donors regenerate the majority of
their liver mass within 1 month of donation, liver fail-
ure requiring possible liver transplantation has been
reported in three donors, and death, in three others.1,2,6
Although the need for adult-to-adult LDLT may
decline with implementation of the Model for End-
Stage Liver Disease liver allocation policy, some critics
have called for a moratorium on adult-to-adult LDLT
until risks and benefits have been clarified in prospec-
tive studies.2,8,9
Many US liver transplant programs also have begun
to use marginal cadaveric donor livers in selected liver
transplant candidates with high medical urgency.10
Marginal cadaveric livers are variably defined as those
with a greater risk for primary nonfunction or the
potential to transmit disease. Preliminary data suggest
that overall patient and graft survival rates have been
acceptable using such carefully selected marginal
donors as those older than 50 years and donor livers
with less than 30% steatosis on biopsy.11,12 Conversely,
results with non–heart-beating donors and severely
steatotic livers have been less favorable.13,14
Hepatitis B core antibody–positive (HBcAb)
cadaveric donor livers also are considered marginal
because of the 25% to 90% risk for hepatitis B virus
(HBV) transmission to the recipient.15,16 However,
outcomes in selected hepatitis B surface antigen
(HBsAg) and seropositive (i.e., HBcAb or antibody
to HBsAg [HBsAb]) recipients generally have been
favorable.15 Transplantation of HBcAb cadaveric liv-
ers to seronegative recipients is associated with a high
rate of HBV transmission, which may lead to severe
graft dysfunction in some recipients.16,17 Use of lami-
vudine and hepatitis B immunoglobulin (HBIG)
immunoprophylaxis in recipients of HBcAb cadaveric
livers appears to reduce the rate of HBV transmission;
however, larger studies with longer follow-up are
needed to determine the optimal prophylaxis strat-
egy.18-20
In this issue of Liver Transplantation, Lo et al21
present outcomes of 54 consecutive adult living liver
transplant donors from Hong Kong who were followed
up for a median of 31 months postdonation. Although
clinical outcomes of a limited number of recipients of
HBcAb living donor liver grafts have been reported
previously, the short- and long-term safety of partial
hepatectomy in HBcAb adult living liver transplant
donors has not been described previously.22,23 The
majority of right-lobe liver donors in this series were
women (65%), and mean donor graft weight was 574 g.
The 24 HBcAb donors were significantly older than
the 29 HBcAb donors (median age, 42 v 31 years).
Interestingly, 80% of the HBcAb group were
HBsAb, suggesting either previous HBV vaccination
or exposure to HBV. However, serum HBV DNA was
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undetectable in all adult living liver transplant donors
before surgery.
HBcAb donors experienced significantly greater
intraoperative blood loss than HBcAb donors (me-
dian, 600 v 350 mL). In addition, the incidence of day
7 cholestasis was greater in HBcAb donors compared
with HBcAb donors (10% v 0%). Intraoperative liver
biopsies showed a greater proportion of HBcAb
donors with hepatic steatosis compared with HBcAb
donors (21% v 12%), and the 3 HBcAb donors with
day-7 cholestasis had evidence of hepatic steatosis. At
last follow-up, all 54 adult living liver transplant donors
were reported to have normal liver biochemistry test
results and no evidence of HBV reactivation, although
laboratory data were not provided.
On univariate analysis, donor age and hepatic ste-
atosis were associated with day 7 cholestasis, whereas
donor HBcAb status was not. It remains unclear
whether HBcAb donors are at increased risk for devel-
oping postoperative cholestasis or whether HBcAb
donors are simply older and more likely to develop
cholestasis from underlying steatosis with impaired
regeneration.24,25 Unfortunately, no qualitative or
quantitative assessment of donor liver regeneration was
reported. The greater intraoperative blood loss
observed in HBcAb donors also may be related to
hepatic steatosis because steatosis has been associated
with increased intraoperative bleeding in patients
undergoing hepatic resection.26 Furthermore, the pres-
ence of hepatic steatosis in 15% of this “thin” group of
Asian liver donors with a median body mass index of
only 20 kg/m2 emphasizes the potential importance of
liver biopsy in donor assessment.1,2,27 Previous studies
of Western patients have shown a lack of reliable clini-
cal features, such as donor sex, body mass index, and
radiological imaging, in identifying living donors with
significant hepatic steatosis preoperatively.27
This interesting observational cohort study suggests
that carefully selected Asian HBcAb adults may be
suitable donors for adult LDLT. The absence of HBV
reactivation in HBcAb donors is surprising because
one would hypothesize that regenerating donor hepa-
tocytes are at risk for infection from integrated HBV
DNA present in the remnant liver. Multiple studies
have shown that HBV DNA can be found in livers of
HBcAb patients with otherwise normal liver bio-
chemistry test results who have completely recovered
from previous HBV infection up to 30 years after expo-
sure.28,29 In addition, HBV DNA was detected in fro-
zen liver tissue of 16 consecutive HBcAb adult living
liver transplant donors in Japan, which was associated
with universal HBV transmission to graft recipients.22
More recent studies of these healthy HBcAb donors
also have shown evidence of replicative forms of HBV,
including covalently closed circular DNA (cccDNA)
and intermediate RNA, in their livers.30 Unfortunately,
data regarding the presence of HBV DNA and hepatitis
B e antigen in HBcAb donors at 1 and 3 months
postdonation are not provided by Lo et al.21 In addi-
tion, the investigators did not perform polymerase
chain reaction for HBV DNA from frozen donor liver
tissue to look for occult HBV infection.
Although continued and careful follow-up of
HBcAb living liver transplant donors is needed, it also
is important to assess outcomes in recipients of
HBcAb grafts. Transplantation of cadaveric HBcAb
livers is more likely to transmit HBV than transplanta-
tion of other solid organs (i.e., kidneys), presumably
because of the greater number of infectious HBV par-
ticles in the donor liver.16 Previous studies from Japan
and Hong Kong show that adult HBcAb living donor
liver grafts are capable of transmitting HBV to 50% to
100% of seronegative recipients.22,23,31 Japanese inves-
tigators proposed to exclude all HBcAb adult living
liver transplant donors because of the high rate of HBV
transmission to the recipient.22 However, they and oth-
ers have shown that the rate of HBV transmission may
be reduced with lamivudine and/or HBIG immuno-
prophylaxis; however, the number of patients treated
and duration of follow-up are limited.22,23
Recently, the Hong Kong group reported a 90%
1-year patient and graft survival rate in HBsAg recip-
ients of 13 cadaveric and 37 adult living donor liver
grafts with lamivudine prophylaxis.30 Surprisingly,
transient expression of HBsAb was detected in 21
HBsAg recipients (42%) within the first 12 months of
transplantation, which was associated with either
HBsAb or HBcAb serostatus in the donor. This
novel observation suggests either adaptive immune
transfer of protective lymphocytes from the seropositive
donor to the recipient or mild self-limited infection of
the recipient with donor HBV.31 Clearly, additional
long-term follow-up of all recipients of HBcAb and
HBsAb adult living donor liver grafts is needed to
follow up on these intriguing preliminary results.
In the United States, recent review articles advocate
excluding HBcAb adult living liver transplant donors
because of the potential risk for: (1) HBV reactivation
in the donor, (2) impaired liver regeneration in the
donor, and (3) HBV transmission to the recipient.1,2
The study by Lo et al21 suggests that HBV reactivation
in carefully selected HBcAb Asian donors is unlikely,
and adequate regeneration presumably can be achieved
in the majority of donors without steatosis.
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However, uncertainty persists regarding the risk for
HBV transmission and the long-term outcome in recip-
ients of these marginal HBcAb living donor liver
grafts. The rate of HBcAb positivity is known to parallel
the overall rate of HBV infection in the general popu-
lation. For example, in such a low endemic country as
the United States, the lifetime risk for exposure to HBV
and having detectable HBcAb is 5%.32 In such moder-
ately endemic areas as Spain or Hong Kong, where the
prevalence of HBsAg positivity is 2% and 10%, the
lifetime risk for HBV exposure and having detectable
HBcAb may be as high as 12% and 33%, respec-
tively.21,33 Therefore, the likelihood of encountering an
HBcAb adult living liver transplant donor during pre-
operative evaluation will vary substantially among pro-
grams in different countries. In most populations, the
prevalence of HBcAb positivity also increases with
age.32,33
Data from the Scientific Registry of Transplant
Recipients (SRTR) indicate that the number of
HBcAb cadaveric livers transplanted in the United
States has increased from 175 livers (3.9%) in 1998 to
248 livers (4.9%) in 2002, with a total of 1,036 livers
(4.5%) transplanted during that period.3 Although
HBsAg patients account for approximately 5% of all
liver transplant recipients, the majority (80%) of cadav-
eric HBcAb livers were transplanted into recipients
with negative or unknown HBsAg serostatus. During
the same period, the number of HBcAb adult living
liver transplant donors in the United States was 2
donors (2.2%) in 1998, 5 donors (1.4%) in 2002, and
43 donors (2.7%) total during that interval. The major-
ity (81%) of HBcAb adult living donor liver grafts
also were transplanted into recipients with negative or
unknown HBsAg serostatus. Unfortunately, the use of
lamivudine and/or HBIG for recipients of either cadav-
eric or adult living donor HBcAb liver grafts is not
reported.
The National Institutes of Health recently assem-
bled the Adult-to-Adult Living Donor Liver Transplant
study group to determine the long-term safety and out-
comes of adult living liver transplant donors and recip-
ients in the United States.34 The study design of this
observational trial includes comparing outcomes of
adult living donor liver transplant recipients with those
of age-, sex-, and disease severity–matched controls
undergoing cadaveric transplantation at the participat-
ing centers. Although larger studies on HBcAb adult
living liver transplant donors are likely to come from
endemic areas, the National Institutes of Health Adult-
to-Adult Living Donor Liver Transplant study group
likely will provide valuable information with the careful
prospective evaluation and collection of blood and liver
tissue samples in both donors and recipients.
Because the prevalence of steatosis and other factors
affecting liver regeneration may be different in Ameri-
can adult living liver transplant donors compared with
Asians, we advocate continuing to exclude HBcAb
adult living liver transplant donors in the United States
until risks and benefits of LDLT in this group of mar-
ginal donors have become better established. We also
recommend that all seronegative adult living liver trans-
plant donors be vaccinated against HBV because they
may be at increased risk for adverse outcomes if they
were exposed to HBV. Furthermore, vaccinating adult
living liver transplant donors for HBsAg recipients
may enhance the recipient immune response to HBV
and improve outcomes; however, additional studies are
needed.31
In summary, rapid proliferation of adult-to-adult
LDLT programs in the United States and abroad dur-
ing the past 5 years has created substantial concern
regarding donor safety.8,9 However, adult-to-adult
LDLT provides a novel opportunity to study and
improve the science of liver transplantation in ways that
are not feasible with cadaveric liver transplantation. In
addition to identifying essential factors involved in liver
regeneration, the LDLT model allows us to conduct
unique natural history studies of primary viral infection
in newly transplanted grafts in a controlled prospective
manner. At this time, we believe that US transplant
programs offering adult-to-adult LDLT should err to
the side of donor and recipient safety and exclude mar-
ginal living liver donors who may be at increased risk for
having poor outcomes (i.e., older donors, steatotic
donors) and those associated with potentially inferior
recipient outcomes (i.e., HBcAb donors).
Future studies of HBcAb adult living liver trans-
plant donors should include protocolized collection of
serum, peripheral-blood mononuclear cells, and frozen
liver tissue before and periodically after donation for
several years. It appears reasonable to target HBcAb
adult living donor livers to either HBsAg or seropos-
itive recipients to minimize the impact of potential
HBV transmission. Last, serum, peripheral-blood
mononuclear cells, and frozen liver tissue samples also
should be collected prospectively in recipients of
HBcAb living liver grafts to determine the natural
history of potential HBV transmission in conjunction
with antiviral and HBIG immunoprophylaxis.
Although adult-to-adult LDLT poses significant poten-
tial risk to the donor, it also provides a unique oppor-
tunity to study disease mechanisms and physiological
processes in a novel unprecedented manner.
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